PubRank

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis (TMC278LA)

Clinical Trial ID NCT02165202

PubWeight™ 5.62‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02165202

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010 50.17
2 Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012 27.84
3 Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012 20.03
4 Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012 15.28
5 Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013 13.72
6 Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008 7.42
7 Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet 2011 5.34
8 Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav 2010 3.08
9 Sentinel surveillance of sexually transmitted infections/HIV and risk behaviors in vulnerable populations in 5 Central American countries. J Acquir Immune Defic Syndr 2007 1.63
10 Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. J Infect Dis 2015 1.45
11 Behavioral and biomedical combination strategies for HIV prevention. Cold Spring Harb Perspect Med 2012 1.03
12 A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. J Acquir Immune Defic Syndr 2016 0.95
13 Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol 2015 0.95
14 Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Antimicrob Agents Chemother 2015 0.85
15 Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S. AIDS Behav 2016 0.84
16 The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine (Lond) 2015 0.76
Next 100